Liquid Biopsy Market worth 1.66 Billion USD by 2021

The report "Liquid Biopsy Market Cancer Type (Lung, Breast, Colorectal, Prostate, Liver), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), Product (Instruments, Software), End User (Reference Laboratory, Research Centers) - Forecast to 2021", provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the liquid biopsy market along with the estimates and forecasts of the revenue.


Browse 75 market data Tables and 74 Figures spread through 160 Pages and in-depth TOC on "Liquid Biopsy Market


Early buyers will receive 10% customization on this report.

The liquid biopsy market is expected to reach USD 1.66 Billion by 2021 from USD 0.58 Billion in 2016, growing at a CAGR of 23.4% during this period.

A number of factors, such as the rising incidence of cancer, benefits of liquid biopsy over solid tumor biopsy, technological advancements, availability of funding, and growing awareness about liquid biopsy through conferences and government initiatives, are driving the growth of the liquid biopsy market. However, unclear regulatory and reimbursement scenario is the major area of concern in this market.

In this report, the liquid biopsy market is segmented on the basis of cancer type, circulating biomarkers, products & services, end users, and regions. Based on cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers. The other cancers segment includes melanoma, bladder cancer, and ovarian cancer. In 2016, the lung cancer segment is expected to account for the largest share of the liquid biopsy market, followed by breast cancer.

Talk to Our Research Analysts for More Info@

Based on circulating biomarkers, the liquid biopsy market is categorized into four major segments, namely, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), Extracellular Vesicles (EVs), and other biomarkers. The other biomarkers segment includes circulating RNA and proteins. The circulating tumor cells segment is expected to account for the largest share of the global liquid biopsy market in 2016, followed by the circulating tumor DNA segment. Based on products and services, the liquid biopsy market is segmented into instruments, reagents, and services and software.

Based on end user, the liquid biopsy market is segmented into reference laboratories, hospital/physician laboratories, academic and research centers, and other end users. The other end-users segment includes public health laboratories, pathology laboratories, and small molecular laboratories.

In 2016, North America is expected to account for the largest share of the global liquid biopsy market. The large share of this regional segment can be attributed to factors such as easy accessibility and high adoption of advanced diagnostic technologies, such as PCR and NGS, among healthcare professionals; increasing prevalence of cancer in the U.S. and Canada; and continuous technological advancements in liquid biopsy. The Asia-Pacific liquid biopsy market, however, is estimated to witness the highest growth during the forecast period owing to the increasing focus of market players on this region.

Get The Sample Copy Of This Report:

Biocept Inc. (U.S.), Myriad Genetics (U.S.), QIAGEN (Netherlands), Roche (Switzerland), Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc. (U.S.), Guardant Health, Inc. (U.S.), Janssen Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft (Germany), and MDxHealth SA (U.S.) are the major players in the liquid biopsy market.

Browse Related Reports:

Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020

Cancer Biomarkers Market by Tumor (Breast, Lung, and Prostate), Type (Protein & Genetic Biomarkers), Profiling Technology (Proteomics, Genomics, Imaging, and Immunoassay), Application (Diagnostic, Drug Discovery, and Prognostic) & Geography - Global Forecast to 2020


About MarketsandMarkets:

MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.


M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.


We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.


Subscribe Reports from Healthcare Domain @


Mr. Rohan

Unit No. 802, 8th Floor, 

Tower - 7, Magarpatta City SEZ,

Hadapsar, Pune – 411013, 

Maharashtra, India.

Tel: +1-888-6006-441.

Visit MarketsandMarkets Blog @

Connect with us on LinkedIn @